170
Views
13
CrossRef citations to date
0
Altmetric
Special Report

Management of polysensitized patient: from molecular diagnostics to biomolecular immunotherapy

, &
Pages 973-976 | Published online: 04 Jul 2015
 

Abstract

A panel of Italian allergists gathered to discuss the issue concerning the management of polysensitized patients. The main conclusions were as follows: polysensitization is a relevant clinical characteristic as it affects about 70–80% of the global allergic population; the diagnostic pathway needs the use of an adequate and thorough methodology, based on the demonstration of consistency between history and documented sensitization; polysensitization and polyallergy are not synonymous: true allergy should always be demonstrated; polysensitization does not constitute a limitation to allergen immunotherapy prescription, as 1–2 allergen extracts could be effective in polysensitized patients; the allergen immunotherapy product characteristics should include the following: high efficacy and optimal safety profile, standardized production, and documented presence and titration of the major allergen.

Financial & competing interests disclosure

The meeting occurred in Bilbao (Spain) on 24–25 October 2014, and was sponsored by Stallergenes Italy. G Ciprandi and C Incorvaia are scientific consultants of Stallergenes Italy. F Frati is the scientific director of Stallergenes Italy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Key issues
  • Polysensitization is a relevant clinical characteristic as it affects about 70–80% of the global allergic population.

  • Diagnostic pathway needs the use of an adequate and thorough methodology, based on the demonstration of consistency between history and documented sensitization by skin prick test and/or serum allergen-specific IgE measurement. In selected patients, molecular diagnostics should be performed.

  • Polysensitization and polyallergy are not synonymous: true allergy should always be demonstrated.

  • Polysensitization does not constitute a limitation to AIT prescription. There is convincing evidence-based medicine literature supporting the concept that 1–2 allergen extracts could be effective in polysensitized patients.

  • The AIT product characteristics should be: high efficacy and optimal safety profile (validated by evidence-based medicine trials for single allergen), standardized production, and documented presence and titration of major allergen.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 718.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.